Soft close RNS?21 Jul 2025 07:10
Elm Grove, WI - July 21, 2025 - Imaging Biometrics, LLC, a leader in quantitative imaging and novel therapeutics for CNS malignancies, today announces a soft close to its Phase 1 clinical trial of oral gallium maltolate (GaM) in adult relapsed or refractory glioblastoma. The trial remains active for currently enrolled participants, with no additional patients being recruited at this time.
-- Does this actually mean that no-one else joined the trial?
IB is actively evaluating the feasibility of independently financing the phase 2 trial while concurrently exploring strategic partnerships.
-- A ploy to prop up the SP?
-- BB ---